Gripe Mixture
Out of date information, search anotherSUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Children’s Gripe Mixture or Gripe Mixture or Infant Sugar Free Gripe Mixture or Children’s 1 Month Plus Gripe Mixture or Boots Gripe Mixture 1 Month Plus
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Active ingredient % Quantity
Sodium Bicarbonate EP 1.0 w/v
3 PHARMACEUTICAL FORM
Liquid
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
For the relief of wind and griping pains.
4.2 Posology and method of administration
For oral administration.
Babies up to 1 month: Not Recommended.
Infants 1 - 6 months: 5 ml.
Infants 6 months - 1 year: 10 ml.
The above doses may be repeated before or after each feed up to six times in 24 hours if needed.
Not recommended for children over 1 year.
4.3 Contraindications
Hypersensitivity to sodium bicarbonate, or any of the ingredients.
Metabolic or respiratory alkalosis
Hypocalcaemia
Hypochlorhydria
Patients on low sodium diets
Congestive heart failure
Oedema/fluid retention
Hypertension/Eclampsia
Impaired renal function
Cirrhosis of the liver
Aldosteronism
Babies under one month of age or over one year of age.
4.4 Special warnings and precautions for use
Do not exceed the recommended dose as excess use may lead to alkalosis.
The medicine should be given to the child to swallow before or after feeds. Inclusion of this medicine in feeds or bottles has not been studied and should be avoided.
Keep all medicines out of the reach of children.
4.5 Interaction with other medicinal products and other forms of interaction
The effect of oral bicarbonate compounds in raising intra-gastric pH may reduce or increase the rate and/or extent of absorption of a number of medicines. Alkalinisation of the urine leads to increased renal clearance of acidic drugs such as salicylates, tetracyclines and barbiturates. Conversely, it prolongs the half life of basic drugs.
Sodium bicarbonate enhances lithium excretion.
4.6 Pregnancy and lactation
The safety of sodium bicarbonate during pregnancy and lactation has not been established, but its use during these periods is not considered to constitute a hazard.
4.7 Effects on ability to drive and use machines
No adverse effects known
4.8 Undesirable effects
Immune system disorders: Rarely hypersensitivity reactions including skin rash
Gastrointestinal disorders: Stomach cramps, belching, flatulence, vomiting
General disorders and administration site conditions: Malaise
Metabolism and nutrition disorders: Excessive use may lead to hypernatraemia and hyperosmolality, hypokalaemia and metabolic acidosis, especially in patients with impaired renal function.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
4.9 Overdose
Overdosage with this medicine may give rise to the symptoms of hypernatraemia, which may include drowsiness and irritability, pyrexia, tachypnoea and hyperpnoea. In more severe instances of acute sodium overload signs of dehydration and convulsions may occur.
Treatment of hypernatraemia includes repair of any dehydration present and the gradual reduction of plasma sodium. The alkalosis, if present, will respond usually to the treatment of Hypernatraemia. At all times, intensive monitoring of electrolytes and patient’s circulation and central nervous system is essential.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Sodium Bicarbonate has antacid properties.
5.2 Pharmacokinetic properties
Sodium bicarbonate causes neutralisation of gastric acid with the production of carbon dioxide. Any bicarbonate not involved in that reaction is absorbed and in the absence of a deficit of bicarbonate in the plasma, bicarbonate ions are excreted in the urine that is rendered alkaline and there is an accompanying diuresis.
5.3 Preclinical safety data
Not applicable.
6.1 List of excipients
Maltitol liquid Glycerol Sodium citrate Domiphen bromide Apple flavour 5112O1E Purified water Carbon dioxide
6.2 Incompatibilities
None stated
6.3 Shelf life
24 months unopened.
12 weeks after opening.
6.4 Special precautions for storage
Do not store above 25 °C
6.5 Nature and contents of container
A clear polythene terephthalate bottle with a polypropylene child resistant closure fitted with an expanded polyethylene liner.
Pack size: 150 ml.
6.6 Special precautions for disposal
None.
7 MARKETING AUTHORISATION HOLDER
The Boots Company Plc 1 Thane Road West
8
9
10
Nottingham NG2 3AA
MARKETING AUTHORISATION NUMBER(S)
PL 00014/5236R
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
20/09/2006
DATE OF REVISION OF THE TEXT
06/02/2014